{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:59:28Z","timestamp":1785326368754,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Myotoxicity, defined as immune-mediated injury to cardiac and\/or skeletal muscle, has emerged as one of the most severe and lethal immune-related adverse events (irAE) in patients receiving immune checkpoint inhibitors (ICIs). Although myocarditis in oncology is not restricted to ICIs and may also occur after traditional cytotoxic chemotherapy, radiotherapy, or selected targeted therapies, ICI-associated cardiomyotoxicity is distinguished by its early onset, frequent overlap with myositis, and myasthenia gravis, and high case-fatality rate. This review outlines myotoxicity within the broader context of cancer therapy-related cardiovascular toxicity, then focuses on the distinct syndromes associated with different immunotherapy classes. For ICIs, we detail a spectrum including myocarditis, myositis, and overlap syndromes, quantified by data from large registries. For Chimeric Antigen Receptor (CAR) T-cell therapy, we focus on cardiotoxicity in the context of cytokine release syndrome (CRS). Diagnostic sections discuss clinical presentation, biomarkers, and imaging, emphasizing the need for troponin I over T and the nuanced interpretation of cardiac magnetic resonance (CMR). The POWER risk score is presented as the first externally validated tool to predict early major adverse cardiomyotoxic events (MACE) from ICIs. Finally, the review proposes distinct management strategies for ICI- versus CAR-T-related toxicity and outlines pragmatic surveillance protocols.<\/jats:p>","DOI":"10.3389\/fonc.2026.1910598","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:03:28Z","timestamp":1785323008000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management"],"prefix":"10.3389","volume":"16","author":[{"given":"Orianne","family":"de la Brassinne Bonardeaux","sequence":"first","affiliation":[{"name":"Department of Cardiology, GIGA Cardiovascular, University of Li\u00e8ge Hospital","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Moonen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, GIGA Cardiovascular, University of Li\u00e8ge Hospital","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Linh","family":"Nguyen Trung","sequence":"additional","affiliation":[{"name":"Department of Cardiology, GIGA Cardiovascular, University of Li\u00e8ge Hospital","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Petitjean","sequence":"additional","affiliation":[{"name":"Department of Cardiology, GIGA Cardiovascular, University of Li\u00e8ge Hospital","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Li\u00e8ge Hospital","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[{"name":"Department of Cardiology, GIGA Cardiovascular, University of Li\u00e8ge Hospital","place":["Li\u00e8ge, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"46","author":"Schulz-Menger","year":"2025","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor\u2013induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study","volume":"47","author":"Salem","year":"2026","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2024.04.004","article-title":"Multimodality imaging of acute myocarditis in cytokine release syndrome (CRS) following CAR-T therapy","volume":"6","author":"Maheswaran","year":"2024","journal-title":"CJC Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag371","article-title":"Immune checkpoint inhibitor myocarditis: a metagenomic investigation of infectious pathogens","author":"Lorca","year":"2026","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B13","article-title":"Cardiovascular complications of immune checkpoint inhibitors, TILs and CAR T-cell therapies","volume":"19","author":"Andres Maria","year":"2025","journal-title":"E-Journal Cardiol Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0046-1822677","article-title":"Beyond the expected: rare immune-related neuromuscular toxicities of checkpoint inhibitors-a real-world experience","author":"Vyas","year":"2026","journal-title":"Indian J Med Paediatr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14360","article-title":"Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor\u2010related myocarditis and myositis: rechallenge","volume":"10","author":"Rossi","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76834","article-title":"Triple M overlap syndrome: myocarditis, myositis and myasthenia gravis after a single administration of pembrolizumab","volume":"17","author":"Baptista","year":"2025","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11897-025-00717-w","article-title":"Cardiac magnetic resonance imaging in immune checkpoint inhibitor\u2013myocarditis: diagnostic and prognostic evidence and limitations","volume":"22","author":"Salem","year":"2025","journal-title":"Curr Heart Fail Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40959-025-00404-8","article-title":"How should immune checkpoint inhibitor myocarditis be treated","volume":"11","author":"Badaan","year":"2025","journal-title":"Cardio-Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/cancers17132063","article-title":"Management of Triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa","year":"2025","journal-title":"Cancers"},{"key":"B23","article-title":"Treatment with anakinra after initially receiving tocilizumab for cytokine release syndrome","volume":"14","author":"Kim","year":"2024","journal-title":"Journalof Hematol Oncol Pharm"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910598\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:03:29Z","timestamp":1785323009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910598\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1910598"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910598","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1910598"}}